2018, Number 09
<< Back Next >>
Ginecol Obstet Mex 2018; 86 (09)
Breast cancer survival after 5 years of treatment: Institutional experience
Heredia-Caballero ÁG, Palacios-López GG
Language: Spanish
References: 14
Page: 575-583
PDF size: 662.18 Kb.
ABSTRACT
Objective: To determine 5-year survival (global and disease-free) and its relationship
with variables: recurrence, clinical stage, histological type and grade, tumoral size,
axillary lymph node invasion and immunohistochemistry.
Materials and Methods: Observational, descriptive and retrospective study
carried out in patients with breast cancer attended in 2010 at the Hospital Militar de la
Mujer, in Mexico City, confirmed by histopathology. The overall survival and diseasefree
to five years has been established from the time elapsed since the diagnosis until
the occurrence of an event (recurrence, metastasis or death) or date of the last contact,
with a limit of December 2015.
Results: 197 records were analysed; however 78 were discarded either: by repetition
of cases (49), due to lack of information (21) and due to recurrences from previous years
(8). The age range were 30 and 84 years, with an average of 56.2 years. The cases in
early stage (CS IIA) was 40%, and overall survival 81% at 5 years. In the patients with
recurrences the probabilities of survival were 51%; and the patients in advanced stages
were less likely to survive. It was not possible demonstrate of statistically significant
association between tumoral size, type and histological grade, immunohistochemistry
and lymph node invasion and survival.
Conclusion: The study shows that patients in the update stages have less likely
to survive, so it is imperative that efforts continue in health promotion until getting the
detection in curable stages.
REFERENCES
Globocan 2012. Fast Stats. Most frequent cancers: both sexes. (Accessed on December 12, 2013).
Miller KD, et al. Cancer treatment and survivorship statisticas, 2016. https://doi.org/10.3322/caac.21349
Bray F, et al. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud pública Mex 2016;58(2):104-117.
Soto-Perez-de-Celis E, et al. National and regional breast cancer incidence and mortality trends in Mexico 2001- 2011: Analysis of a population-based database. https:// doi.org/10.1016/j.canep.2016.01.007
Leal YA, et al. The importance of registries in cancer control. Salud pública Mex 2016;58(2):309-316.
Lozano-Ascencio R y col. Tendencias del cáncer de mama en América Latina y El Caribe. Salud pública Mex 2009;51(3):147-156.
Knaul FM, et al. Breast cancer in Mexico: a pressing priority. https://doi.org/10.1016/S0968-8080(08)32414-8
Lara-Medina F, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. https://doi.org/10.1002/cncr.25961
Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario, quinta revisión, Colima 2015.
Allemani C, et al. Breast cancer survival in the US and Europe: A CONCORD high-resolution study. Int https://doi. org/10.1002/ijc.27725
Secretaría_de_Salud_México. NOM-041-SSA2-2011, Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama. Diario Oficial de la Federación 2011. 19
Base de datos SEER del National Cancer Institute.
Ocon-Hernandez Olga, y col. Supervivencia en cáncer de mama tras 10 años de seguimiento en las provincias de Granada y Almeria. Rev Esp Salud Publica, 2010, 84: 705-715.
Chen Lu, et al. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. https://doi.org/10.1007/s10549-014-3112-6
Full text